Close this search box.

DarolutamidE + Consolidation Radiotherapy in Advanced prostate cancer detected by PSMA

In the era of PET imaging, many sites of disease that are not visible on conventional imaging will be found on PSMA (prostate specific membrane antigen) PET. For men with castration-resistant prostate cancer with no evidence of metastases on conventional imaging but detectable disease on Prostate Specific Membrane Antigen (PSMA)-PET/CT scan, DECREASE will compare the treatment outcomes of men taking Darolutamide with or without treating the small metastasis seen on the PSMA PET scan with radiation therapy. Lead by A/Profs Shankar Siva and Arun Azad, DECREASE aims to determine that the combination (Darolutamide + RT) is better than Darolutamide alone at controlling PSA levels and further spread of prostate cancer.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups


Participating Centres

Accrual Target


Current Accrual

Trial Chairperson

A/Prof Shankar Siva, Peter MacCallum Cancer Centre, VIC
A/Prof Arun Azad, Peter MacCallum Cancer Centre, VIC

Trial Contact

Clinical Trial Registration

Related Post

October 18, 2022

NINJA Radiation Therapy Trial participant tells his journey to treatment

The journey to becoming the 200th participant for the

September 6, 2022

The gift that kept on giving

The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing